Poumon | Nano Publications

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Immune checkpoint inhibitors (ICIs) have led to improved treatment outcomes in a variety of cancers; however, the majority of patients exhibit resistance to ICIs. Overcoming this resistance is a major challenge in immune-oncology. Radiation therapy (RT) has emerged as a promising combination with ICIs since it may act synergistically with ICIs by producing an immunomodulatory effect. […]

Continuer la lecture…

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Continuer la lecture…

2021 – NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in patients with advanced cancers: phase I trial

Abstracts, Donnée clinique de NBTXR3, Foie, Non classifié(e), Poumon, Tête & Cou

Immune checkpoint inhibitors (ICIs) have improved treatment outcomes in a variety of cancers; however the majority of patients (pts) exhibit resistance. Emerging evidence suggests radiation therapy (RT) can enhance response to ICIs by producing an immunomodulatory effect. NBTXR3, composed of functionalized hafnium oxide nanoparticles, is injected intratumorally and activated by RT. […]

Continuer la lecture…

2020 – Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Continuer la lecture…

2020 – Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy

Abstracts, Donnée clinique de NBTXR3, Foie, NO-RIGHTS, Poumon, Tête & Cou

Despite the past decade of transformative advances in immuno-oncology, the response rate to checkpoint inhibitors (ICIs) remains low (~15%). There is significant interest in developing strategies to overcome resistance to these treatments, thus increasing response rate. Emerging evidence suggests that radiation therapy (RT) could potentially augment the antitumor response to ICIs through synergic effect. […]

Continuer la lecture…

2020 – SITC – NBTXR3 with Anti-PD-1 Therapy

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Cancer immunotherapies have shown promising clinical outcomes; however, the majority of patients are non-responders or will develop resistance during the course of treatment. One of the current challenges is to increase the response rate to immune checkpoint inhibitors (ICIs). Combining immunotherapy with radiation therapy (RT) is emerging as a valuable strategy to prime the immune response. However, RT dose and ultimate efficacy are limited by toxicity related to exposure of healthy tissues. […]

Continuer la lecture…

2020 – ASTRO – NBTXR3 in Combination with Anti-PD-1

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Immune checkpoint inhibitors (ICIs) are being increasingly used to improve patient outcomes across different cancer types. However, the response rate to ICIs remains low (~15%), indicating the need for novel strategies to improve treatment outcome. Emerging evidence suggests that radiation therapy (RT) could potentially enhance the antitumor response and provide synergy with ICIs. RT dose and ultimate efficacy are however limited by toxicity related to exposure of healthy tissues. […]

Continuer la lecture…

2020 – ASCO – NBTXR3 With Anti PD1 Therapy

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Continuer la lecture…

2020 – ASCO-SITC – NBTXR3 with anti-PD-1 therapy

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Most cancer patients present resistance to immune therapy; only approximately 15% of patients respond to immune checkpoint inhibitors (ICI). Strategies able to increase ICI response are thus of great interest. Radiotherapy (RT), by acting as an immunomodulator is a good candidate to increase the proportion of ICI responders. However, RT dose and ultimate efficacy are limited by potential toxicity to healthy tissues. NBTXR3, a first in class radioenhancer administered by intratumoral injection, has been designed at the nanoscale to increase RT energy dose deposition within the tumor. […]

Continuer la lecture…

2019 – A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With an Anti-PD-1 Therapy

Abstracts, Donnée clinique de NBTXR3, Abstracts, Donnée clinique de NBTXR3, Foie, Tête & Cou, Foie, Poumon, Poumon, Tête & Cou

The majority of cancer patients are resistant to immune therapy; only around 15% respond to immune checkpoint inhibitors (ICI). Thus, strategies able to increase ICI response are of great interest. Recent work suggests radiotherapy (RT) can act as an immunomodulator to increase the proportion of ICI responders and improve clinical outcomes. […]

Continuer la lecture…